State data from 2018 through 2022 shows prostate cancer is the leading cancer diagnosis in Cuyahoga County, yet 77% of cases ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), ...

A Shropshire hospital trust says patients with prostate cancer are benefitting from greater survival rates thanks to a ...

The effects of the extent of lymph node dissection during radical prostatectomy on prostate cancer survival outcomes have been unclear, pending long-term follow-up data from randomized controlled ...

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...

Bellmunt Risk Score predicts survival in mCRPC across treatment lines. Learn how this simple tool can guide prognosis and treatment decisions. Read more.

A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.

Pfizer reported positive topline results in its phase three study of talazoparib in combination with enzalutamide to treat metastatic hormone-sensitive prostate cancer. The study met its primary ...

Pfizer (PFE) stock is in focus as Xtandi, marketed with Astellas (ALPMF), and cancer drug Talzenna succeed in a Phase 3 trial for prostate cancer. Read more here.

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). | After an FDA snub in a broader metastatic ...

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.